// Our Vision
Developing Life-Saving Cancer Treatments
At Myeloid, we have applied our extensive knowledge of advanced gene and cell therapies to build novel platform technologies that harness the innate abilities of myeloid cells. We have translated the learnings from our backgrounds and novel platform to create a clinical-stage, mRNA-immunotherapy pipeline focused on breakthrough therapies for cancer.
// OUR HISTORY
A Track Record of
A Track Record of
Myeloid launched with over $50 million in financing and two clinical trials in glioblastoma and T cell lymphoma.
Building the Team
Myeloid began to build out its key leadership positions and board members.
AACR 2022 Presentation
Myeloid presented data in a late-breaking session at AACR 2022 on in vivo delivery and ATAK CAR receptors.
Exclusive Option and Research Collaboration
Myeloid entered into an exclusive option and research collaboration with PRIME Medicine for RetroT™.
First Patient Dosed
Myeloid dosed the first patient with its MT-101 cell therapy product in the IMAGINE Phase 1/2 clinical study.
Agreement with Acuitas
Myeloid entered into agreement with Acuitas for the Lipid Nanoparticle (LNP) System, enabling the first-ever delivery of mRNA-encoded CARs directly to humans.
Strengthening of Board of Directors
Myeloid strengthened its board of directors with the appointments of Stanley Frankel, MD, and Brett Kaplan, MD.
Fast Track Designation
Myeloid received Fast Track Designation from the US FDA for MT-101 for the treatment of CD5+ Relapsed/Refractory PTCL.
Proof-Of-Concept Data in Primates
Myeloid presented proof-of-concept data in primates delivering in vivo mRNA TROP-2 targeting CAR (MT-302) at the Society for Immunotherapy of Cancer (SITC) 37th annual meeting.
JP Morgan Meeting
Myeloid delivered an oral presentation at the JP Morgan 2023 meeting.
New South Wales Government Collaboration
Myeloid entered into collaboration with the New South Wales Government to build a state-of-the-art GMP Facility dedicated to RNA immunotherapies.
Myeloid presented late-breaking data at multiple platforms at AACR.